FDA accepts new drug application for Merck’s Doravirine/Islatravir
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Subscribe To Our Newsletter & Stay Updated